XRP and stablecoins are not rivals, XRPL validator says
A debate among XRP Ledger community figures has put fresh focus on how stablecoins, payments and XRP may work together on XRPL.
- XRPL validator Vet said XRP and stablecoins are complementary parts of the payment stack.
- Eri argued Ripple has used stablecoins to bridge ODL while keeping XRPL liquidity important too.
- The debate centers on whether neutral native assets can reduce fragmented liquidity across payment routes.
In an Eri post, the researcher said Ripple has used Tether and USDC stablecoins to support On-Demand Liquidity flows, while liquidity on XRPL remains central.
Eri also said XRP has use cases outside payments, including collateral and DeFi. The post pointed to future financial products on XRPL that may use XRP in ways beyond simple transfer settlement.
Stablecoin sandwich gets clarified
Vet, an XRPL dUNL validator and XRPL Foundation contributor, responded that he sees “XRP and Stablecoins as complementary parts of the stack.” In a Vet post, he said a stablecoin sandwich works like a normal payment, not a cross-currency payment.
He said local currency swaps can happen at the sender and receiver ends. In that setup, the swap does not need to happen on-chain or touch the XRPL DEX. Still, he said quality assets and stablecoins are needed so service providers can build reliable payment flows.
In addition, Vet argued that once many issued currencies exist on-chain, markets still need a bridge asset. Without one, liquidity can split across too many direct pairs. He said XRP can serve that role on the XRP Ledger when a bridge transaction makes sense.
As crypto.news reported earlier, XRPL Foundation’s AMM proposal would add StableSwap and concentrated liquidity to improve stablecoin, RWA and DeFi pricing. The proposal aims to reduce slippage for assets that trade close to the same value, including stablecoins.
XRP’s neutral bridge role stays debated
Vet said an issued asset should not become the main bridge asset on a decentralized network because regulated issuers follow local laws. He argued that native assets are better suited for neutral bridging where no single issuer controls the system.
According to an earlier crypto.news report, RLUSD’s 40-chain rollout expanded Ripple’s stablecoin access for payments, tokenization and institutional liquidity. crypto.news previously reported that XRP Ledger utility beyond payments is moving into tokenized assets, DeFi and lending.
The debate does not settle whether stablecoins reduce or strengthen XRP demand. It shows that XRPL builders see the two as separate tools. Stablecoins may handle routes where price-stable settlement works, while XRP may still matter where neutral cross-asset liquidity is needed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
